养血清脑颗粒联合小剂量盐酸多塞平治疗非器质性失眠症的临床观察

The clinical observation of Yangxue Qingnao granules combined with small dose of doxepin hydrochloride on non-organic insomnia

目的探讨养血清脑颗粒联合小剂量盐酸多塞平治疗非器质性失眠症的临床疗效。方法选择我院收治的96例非器质性失眠症患者,根据随机数字表法,将96例患者分为观察组及对照组,观察组患者给予小剂量的盐酸多塞平联合养血清脑颗粒进行治疗,对照组患者仅给予小剂量的盐酸多塞平进行治疗。观察两组患者治疗8周后的治疗效果,治疗前、治疗4周、治疗8周的PSQI总评分及不良反应发生情况。结果治疗8周后,观察组的治疗总有效率(97.9%)明显高于对照组(87.5%)(P<0.05)。治疗4周及8周,两组患者的PSQI总评分均较治疗前明显下降(P<0.05);治疗前及治疗4周后,两组患者的PSQI总评分对比差异无统计学意义(P>0.05);而治疗后8周,观察组的PSQI总评分明显低于对照组(P<0.05)。观察组与对照组的不良反应发生率对比,差异无统计学意义(P>0.05)。结论养血清脑颗粒联合小剂量盐酸多塞平治疗非器质性失眠症安全、有效,值得临床推广应用。

Objective To investigate the clinical efficacy of Yangxue Qingnao granule combined with small dose of doxepin hydrochloride on patients with non-organic insomnia. Methods Ninety-six patients with non-organic insomnia in our hospital were chosen and divided into observation group and control group according to the random number table. The observation group was given small dose of doxepin hydrochloride combined with Yangxue Qingnao granules, while the control group was taken small dose of doxepin hydrochloride. The efficacy in 8 weeks after treatment, PSQI total scores before treatment, 4 and 8 weeks after treatment, and adverse reaction incidence rate of the two groups were compared. Results Eight weeks after treatment, the total efficacy rate in the observation group （97.9%） was significantly higher than that in the control group （87.5%） （P〈0.05）. The PSQI total scores of two groups were significantly decreased compared with that before treatment （P〈0.05）. The PSQI total scores before treatment and in 4 weeks after treatment of two groups had no significant difference （P〉0.05）; the PSQI total score in 8 weeks after treatment of the observation group was significantly lower than that in the control group （P〈0.05）. The adverse reactions incidence of two groups had no statistical significance （P〉0.05）. Conclusion Yangxue Qingnao granules combined with small dose of doxepine hydroehloride for non-organic insomnia is safe and effective, which is worthy of clinical promotion and application.